Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1514)	8/29/2004 3:57:31 PM
From: Icebrg	Respond to of 1826

MGI Pharma "outperform" Monday, August 16, 2004 8:22:40 AM ET Robert W. Baird NEW YORK, August 16 (New Ratings) - Analysts at Robert W Baird maintain their "outperform" rating on MGI Pharma (MOGN.NAS). The target price is set to $35. In a research note published this morning, the analysts mention that the company's share price is under significant pressure on account of reimbursement related issues. MGI Pharma's near-term results are, however, expected to be robust, the analysts say. The company's stock is attractively valued at present, according to Robert W Baird.